HMG-CoA reductase inhibitors

USRE36481E · kind E · reissue

Assignee

• MERCK & CO., INC. · US

Inventors

• Edward S. Inamine · Rahway, US
• Otto D. Hensens · Red Bank, US
• David Renwick Houck · Cary, US
• Ta J. Lee · Lansdale, US
• Robert L. Smith · Lansdale, US
• Wasyl Halczenko · Lansdale, US
• George D. Hartman · Lansdale, US
• Gerald E. Stokker · Gwynedd Valley, US

Key dates

• Filing date: Nov 4, 1998
• Grant date: Jan 4, 2000
• Expiry date: Nov 4, 2018

Classification

• Technology area (CPC —): General

Abstract

RACTS Circulation, vol. 70, Supp. II, p. 268, No. 1072 (1984). D. W. Bilheimer et al., "Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes", Proc. Natl. Acad. Sci. USA, vol. 80, pp. 4124-4128 (Jul. 1983). D. W. Bilheimer et al., "Mevinolin Stimulates Receptor-Mediated Clearance of LDL in Familial Hypercholesterolemia (FH) Heterozygotes", Clin. Res. 31, No. 2, p. 544A (1983). J. A. Tobert et al., Cholesterol-lowering effect of Mevinolin, an Inhibitor of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase, in Healthy Volunteers, J. Clin. Invest. (USA), 69(4), PP. 913-919 (Apr. 1982). J. A. Tobert et al., "Rapid and Substantial Lowering of Human Serum Cholesterol by Mevinolin (MK-803), An Inhibitor of Hydroxymethylglutaryl-Coenzyme A Reductase", Atherosclerosis, 41, pp. 61-65 (1982). LREP FR2 Quagliato; Carol S. FR2 Winokur; Melvin